ClinicalTrials.gg
CompletedNCT00327171Updated Jun 7, 2016Results posted

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

A Phase 2 interventional study of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) and Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) in Neoplasms and Cancer of the Ovary, sponsored by Sanofi. Completed at 11 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-07.

Primary conditionOvarian NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ovarian Neoplasms
Why
  1. The study's listed conditions name Ovarian Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies in Ovarian Neoplasms by Sanofi — none open to participants now, none under way, none of them phase 3. Ovarian Neoplasms · Sanofi.

Enrollment
Largest of 13
218 · median 47
Started
2006
with 3 others
Phase 2
9 of 14
none open now
Registered
3rd of 14
by date

Among the 14 studies in Ovarian Neoplasms by Sanofi, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2006, is one of 9 in phase 2, and was the 3rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 14 studies in Ovarian Neoplasms by Sanofi is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 601 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Ovarian Neoplasms by Sanofi as a file.
02

Study summary

This study evaluated outcomes in participants with advanced ovarian epithelial adenocarcinoma receiving aflibercept.

The primary objective was to compare the objective response rate of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg and 2.0 mg/kg, administered intravenously (IV) every 2 weeks with historical control in participants with advanced ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma resistant to platinum and topotecan and/or liposomal doxorubicin.

The secondary objectives was to further assess efficacy, safety, pharmacokinetics, potential biological and pharmacogenomic markers of study drug activity, and health-related quality of life.

This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. If an endpoint was evaluated by the IRC, the IRC reviewed data is reported for this study.

Read the detailed description

The study included:

  • A screening period for 21 days
  • Randomization at baseline (Treatment was initiated with 5 days of randomization)
  • A treatment period with 14-day study treatment cycles until a study withdrawal criterion was met
  • A follow-up period up to 60 days after the end of treatment

Withdrawal criteria that led to treatment discontinuation were:

  • The participant or their legally authorized representative requested to withdraw
  • In the investigator's opinion, continuation of the study would be detrimental to the participant's well being, due to reasons such as disease progression, unacceptable toxicity, noncompliance, or logistical considerations.
  • A specific request by the Sponsor
  • Participant had intercurrent illness that prevented further administration of study treatment
  • Participant had more than 2 aflibercept dose reductions
  • Participant had arterial thromboembolic events, including cerebrovascular accidents, myocardial infarctions, transient ischemic attacks, new onset or worsening of pre-existing angina
  • Participant had radiographic evidence of intestinal obstruction (e.g., dilated loops of bowel accompanied by air-fluid levels) or gastrointestinal perforation (e.g., presence of extraluminal gas) requiring surgical intervention
  • Participant was lost to follow-up

After discontinuing treatment, participants remained on the study until the last post-treatment visit or until recovery of drug related toxicities, whichever was later.

03

Conditions studied

  • Neoplasms
  • Cancer of the Ovary

Browse trials for

Keywords

  • ovarian cancer
  • angiogenesis
  • angiogenesis inhibition
  • VEGF-Trap fusion recombinant protein
  • Cancer and other neoplasms
04

In context

Ovarian Neoplasms Reclassified

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

This study's enrollment of 218 is above the median of 54 across 2,555 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Compared within Ovarian Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Participants who met the following criteria were eligible for the study.

Inclusion criteria

Inclusion Criteria:

  • -confirmed ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma.
  • Prior treatment with at least 2 treatment regimens in the advanced disease treatment setting
  • Platinum-resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance
  • Topotecan- and/or liposomal doxorubicin-resistant disease defined by relapse or progression of disease during or after treatment, or drug intolerance
  • Evidence of at least one unidimensional measurable tumor lesion by computed tomography (CT) or magnetic resonance imaging (MRI) scan according to (RECIST) that has not been treated with surgery or radiation therapy

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any second within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri
  • Prior treatment with a vascular endothelial growth factor (VEGF) or VEGF receptor inhibitor
  • More than 3 chemotherapy regimens in the advanced disease treatment setting
  • Uncontrolled hypertension

The above information is not intended to contain all considerations relevant to potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Aflibercept 2.0 mg/kg

    Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

  • Experimental
    Aflibercept 4.0 mg/kg

    Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.

    Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Interventions

  • Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks. Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.

  • Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks. Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.

07

What researchers measure

Primary outcomes

  1. Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort

    OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  2. Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population

    OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

Secondary outcomes

  1. Number of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC

    CBR was defined as having a Stable disease (SD) for \>= 6 months or a confirmed OR (PR or CR). Based on RECIST: * SD was neither a sufficient shrinkage of the target lesions to qualify for PR nor sufficient increase to qualify for Progressive disease (PD), the persistence of non-target lesions or the maintenance of tumor marker level above the normal limits (for non-target lesions) * CR was the disappearance of all target or non-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  2. Duration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC)

    DR was defined as the time interval from the first documentation of CR or PR to the date of tumor progression (or disease progression) as determined by RECIST, or death from any cause, whichever was earlier. Based on RECIST, progressive disease was at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, the appearance of one or more new target or non-target lesions, or the unequivocal progression of existing non-target lesions.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  3. Tumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition

    TMRR was the proportion of evaluable participants achieving a cancer antigen -125 (CA-125) response based on GCIG definition. A response to CA-125 occurred if after two elevated levels before therapy there was at least a 50% decrease in a post-treatment serum sample, which was confirmed by an independent sample collected 21 days or later that was =\< 110% of the post-treatment serum sample.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  4. Time to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC

    TTP was defined as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST. TTP was estimated from Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  5. Time to Tumor Marker (CA-125) Progression (TTMP)

    TTMP was the time interval from the date of randomization to the date of tumor marker progression as was defined by GCIG for the evaluable participants. TTMP was estimated using Kaplan-Meier curves. For a participant who did not reach tumor marker progression (TMP) during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  6. Number of Participants With Disease Progression Events for Progression-free Survival (PFS) Analysis by the IRC.

    PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. The number of participants with tumor/disease progression are reported. Participants who did not reach tumor progression during study, or had no valid post-baseline tumor burden assessment due to early termination, were censored in the PFS analysis.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  7. Progression-free Survival (PFS) Time Based on Analysis by the IRC

    PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. PFS was estimated using Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  8. Overall Survival (OS) Time

    OS was the time interval between randomization and the date of death from any cause. OS was estimated using Kaplan-Meier curves A participant was censored for the OS analysis if the participant were alive during the study. The censoring date was either at the date that the participant was last known to be alive or the date of study cut-off, whichever was earlier.

    Time frame: From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)

  9. Overall Safety - Number of Participants With Adverse Events (AE)

    All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

    Time frame: up to 30+/-5 days after treatment discontinuation, or up to recovery or stabilization of a followed-up adverse event

  10. Participant's Assessment of Health Related Quality of Life (HRQL) Using a by Using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Questionnaire

    The FACT-O questionnaire consists of 38 scored questions (scored from 0-4) that address physical well-being, social/family well-being, emotional well-being, functional well-being and some additional concerns which relate specifically to ovarian cancer symptoms. For each question, higher scores reflect a better quality of life. The total FACT-O score ranges from 0-152, with 152 indicating the best outcome.

    Time frame: On Day 1 of Cycle 1 (baseline) , and after Day 14 of Cycle 2

08

Results

Posted Oct 18, 2012

Participant flow

218 participants were randomized in this study. Three participants in the 2 mg/kg treatment group did not receive any study medication.

Participant flow — Overall Study
MilestoneAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Started109109
Completed10
Not completed108109
Withdrew: Did not receive study medication30
Withdrew: Adverse event2323
Withdrew: Disease progression/lack of efficacy6869
Withdrew: Investigator/participant request18
Withdrew: Clinical progression128
Withdrew: Undisclosed history of ischemia01
Withdrew: Other10

Outcome measures

PrimaryNumber of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort

OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Number · participants
Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort
participantsAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort03
SecondaryNumber of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC

CBR was defined as having a Stable disease (SD) for \>= 6 months or a confirmed OR (PR or CR). Based on RECIST: * SD was neither a sufficient shrinkage of the target lesions to qualify for PR nor sufficient increase to qualify for Progressive disease (PD), the persistence of non-target lesions or the maintenance of tumor marker level above the normal limits (for non-target lesions) * CR was the disappearance of all target or non-target lesions; and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with reference to the baseline sum LD.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Number · participants
Number of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC
participantsAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Number of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC127
SecondaryDuration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC)

DR was defined as the time interval from the first documentation of CR or PR to the date of tumor progression (or disease progression) as determined by RECIST, or death from any cause, whichever was earlier. Based on RECIST, progressive disease was at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, the appearance of one or more new target or non-target lesions, or the unequivocal progression of existing non-target lesions.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Mean · days
Duration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC)
daysAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Duration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC)164 ± NA149.8 ± 70.4
SecondaryTumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition

TMRR was the proportion of evaluable participants achieving a cancer antigen -125 (CA-125) response based on GCIG definition. A response to CA-125 occurred if after two elevated levels before therapy there was at least a 50% decrease in a post-treatment serum sample, which was confirmed by an independent sample collected 21 days or later that was =\< 110% of the post-treatment serum sample.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Mean · percentage of participants
Tumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition
percentage of participantsAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Tumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition11.5 (4.7 to 22.2)11.6 (5.1 to 21.6)
SecondaryTime to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC

TTP was defined as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST. TTP was estimated from Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Median · weeks
Time to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC
weeksAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Time to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC13.1 (12.1 to 16.7)12.7 (12 to 18.9)
Statistical analysis
  • Aflibercept 2.0 mg/kg vs Aflibercept 4.0 mg/kg · Log Rank · p = 0.5043 · Hazard ratio (hr): 1.123 · 95% CI 0.80 to 1.58Estimated using Cox proportional Hazard model using treatment as the factor
SecondaryTime to Tumor Marker (CA-125) Progression (TTMP)

TTMP was the time interval from the date of randomization to the date of tumor marker progression as was defined by GCIG for the evaluable participants. TTMP was estimated using Kaplan-Meier curves. For a participant who did not reach tumor marker progression (TMP) during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Median · weeks
Time to Tumor Marker (CA-125) Progression (TTMP)
weeksAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Time to Tumor Marker (CA-125) Progression (TTMP)NA (24.1 to NA)NA (22.7 to NA)
SecondaryNumber of Participants With Disease Progression Events for Progression-free Survival (PFS) Analysis by the IRC.

PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. The number of participants with tumor/disease progression are reported. Participants who did not reach tumor progression during study, or had no valid post-baseline tumor burden assessment due to early termination, were censored in the PFS analysis.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Number · participants
Number of Participants With Disease Progression Events for Progression-free Survival (PFS) Analysis by the IRC.
participantsAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
With disease progression as the first event6666
Death without disease progression1623
Censored due to drop-out1814
Censored at study cut-off66
SecondaryProgression-free Survival (PFS) Time Based on Analysis by the IRC

PFS was as the time interval measured from the date of randomization to the date of tumor progression as determined by RECIST or death from any cause, whichever was earlier. PFS was estimated using Kaplan-Meier curves. For a participant who did not reach tumor progression during study, the censoring date was the date of the last valid tumor burden assessment or the date of study cut-off, whichever was earlier. If the participant had no valid post-baseline tumor burden assessment due to early termination, the censoring date was the date of randomization.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Median · weeks
Progression-free Survival (PFS) Time Based on Analysis by the IRC
weeksAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Progression-free Survival (PFS) Time Based on Analysis by the IRC13.0 (11.7 to 16.7)13.3 (11.2 to 18.9)
Statistical analysis
  • Aflibercept 2.0 mg/kg vs Aflibercept 4.0 mg/kg · Log Rank · p = 0.5592 · Hazard ratio (hr): 1.093 · 95% CI 0.81 to 1.48Estimated using Cox proportional Hazard model using treatment as the factor (4mg/kg vs. 2mg/kg)
SecondaryOverall Survival (OS) Time

OS was the time interval between randomization and the date of death from any cause. OS was estimated using Kaplan-Meier curves A participant was censored for the OS analysis if the participant were alive during the study. The censoring date was either at the date that the participant was last known to be alive or the date of study cut-off, whichever was earlier.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Median · weeks
Overall Survival (OS) Time
weeksAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Overall Survival (OS) Time59.0 (41.6 to 84.1)49.3 (37.4 to 62.7)
Statistical analysis
  • Aflibercept 2.0 mg/kg vs Aflibercept 4.0 mg/kg · Log Rank · p = 0.5457 · Hazard ratio (hr): 1.124 · 95% CI 0.77 to 1.64Estimated using Cox proportional Hazard model using treatment as the factor (4 mg/kg vs. 2mg/kg)
PrimaryNumber of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population

OR included Complete Response (CR) and Partial Response (PR). Per RECIST, CR was disappearance of all target or non-target lesions, or normalization of tumor marker levels (for non-target lesions) and PR was at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, with baseline sum LD as reference. Tumors were assessed by an independent third-party core imaging laboratory evaluating the chest, abdomen, and pelvis by Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and responses were confirmed by repeat tumor imaging 4-6 weeks later.

Time frame:
From enrollment to efficacy cut-off date, 18 January 2008 (approximately 20 months)
Reported as:
Number · participants
Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population
participantsAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population15
SecondaryOverall Safety - Number of Participants With Adverse Events (AE)

All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization. The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported.

Time frame:
up to 30+/-5 days after treatment discontinuation, or up to recovery or stabilization of a followed-up adverse event
Reported as:
Number · participants
Overall Safety - Number of Participants With Adverse Events (AE)
participantsAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
With any TEAE106108
With any serious TEAE5055
With any TEAE leading to death1414
With TEAE leading to treatment discontinuation2324
SecondaryParticipant's Assessment of Health Related Quality of Life (HRQL) Using a by Using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Questionnaire

The FACT-O questionnaire consists of 38 scored questions (scored from 0-4) that address physical well-being, social/family well-being, emotional well-being, functional well-being and some additional concerns which relate specifically to ovarian cancer symptoms. For each question, higher scores reflect a better quality of life. The total FACT-O score ranges from 0-152, with 152 indicating the best outcome.

Time frame:
On Day 1 of Cycle 1 (baseline) , and after Day 14 of Cycle 2
Reported as:
Mean · score on a scale
Participant's Assessment of Health Related Quality of Life (HRQL) Using a by Using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Questionnaire
score on a scaleAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Baseline (N=97, N=104)105.3 ± 20.0101.1 ± 22
Change (baseline to Cycle 2-Day 14) (N=79, N=77)-1.1 ± 12.7-2.8 ± 13.9

Adverse events

Collected over From treatment initiation to June 9, 2010. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2.0 mg/kg—51/106 (48.1%)105/106 (99.1%)
Aflibercept 4.0 mg/kg—56/109 (51.4%)106/109 (97.2%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
Intestinal obstructionGastrointestinal disorders10/1066/109
Disease progressionGeneral disorders3/1067/109
Abdominal painGastrointestinal disorders4/1066/109
HypertensionVascular disorders4/1066/109
DehydrationMetabolism and nutrition disorders4/1062/109
DyspnoeaRespiratory, thoracic and mediastinal disorders2/1064/109
NauseaGastrointestinal disorders3/1060/109
Renal failureRenal and urinary disorders3/1063/109
Pleural effusionRespiratory, thoracic and mediastinal disorders3/1061/109
AnaemiaBlood and lymphatic system disorders2/1061/109
Most frequent other events
Showing 10 of 45
Most frequent other events
EventAflibercept 2.0 mg/kgAflibercept 4.0 mg/kg
HypertensionVascular disorders60/10657/109
HeadacheNervous system disorders54/10654/109
DysphoniaRespiratory, thoracic and mediastinal disorders39/10646/109
NauseaGastrointestinal disorders44/10643/109
FatigueGeneral disorders42/10644/109
Decreased appetiteMetabolism and nutrition disorders42/10630/109
Abdominal painGastrointestinal disorders36/10640/109
VomitingGastrointestinal disorders38/10630/109
DiarrhoeaGastrointestinal disorders31/10639/109
ConstipationGastrointestinal disorders37/10627/109

Baseline characteristics

Age, Customized
Age, Customized(participants)Aflibercept 2.0 mg/kgAflibercept 4.0 mg/kgTotal
<35 years336
>=35 to <45 years10616
>=45 to <55 years212546
>=55 to <65 years374380
>=65 to <75 years322557
>=75 years6713
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2.0 mg/kgAflibercept 4.0 mg/kgTotal
Female109109218
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Aflibercept 2.0 mg/kgAflibercept 4.0 mg/kgTotal
Caucasian104107211
Black314
Asian, Oriental112
Unknown or Not Reported101
09

Study locations

11 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Macquarie Park, Australia
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
  • Sanofi-Aventis Administrative Office
    Milano, Italy
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Porto Salvo, Portugal
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Bromma, Sweden
  • Sanofi-Aventis Administrative Office
    Geneva, Switzerland
10

References and documents

Publications

  • Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, Matei D, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer. 2014 Feb 1;120(3):335-43. doi: 10.1002/cncr.28406. Epub 2013 Oct 11. PubMed 24127346 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Apr 2008 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 4 years 6 months after primary completion. A results delay was requested in Aug 2011.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2006
First posted
May 18, 2006
Start
May 2006
Primary completionActual
Apr 2008
CompletionActual
Mar 2010
Results delay requested
Aug 8, 2011
Results first posted
Oct 18, 2012
Last update
Jun 7, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00327171
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 18, 2006
Start date
May 2006
Primary completion
Apr 2008
Completion
Mar 2010
Results posted
Oct 18, 2012
Last update
Jun 7, 2016

Study contacts

ICD CSD
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion